A Special Emphasis Panel of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will convene in a closed session on May 21, 2020 to review contract proposals submitted for NIAID Omnibus BAA 2020-1: Research Area 004—Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases.
The objective of this NIAID Broad Agency Announcement Research Area is the development of promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens. For the purposes of this solicitation, therapeutic activity is defined as the cure or mitigation of disease, preferably, once signs and symptoms of infection are evident. For the purposes of this solicitation, a therapeutic candidate is either a lead series, lead, or product candidate, and is either a drug (synthetic or natural product) or a biological product (e.g. monoclonal antibodies, recombinant proteins).
This Research Area supports lead optimization, pre-clinical (IND enabling) and clinical trials that include Phase 1 and Phase 2 studies.
NIAID estimates that three or more awards may be issued for a total cost of up to $11.5 million for the non-severable base work across all contracts (direct and indirect costs combined).
According to the Federal Register announcement, the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, stating “contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.”
